Sugi Predict

Sugi Predict / Compounds / Z-Astringin

Z-Astringin

Z-Astringin

SCHEMBL501245

OC[C@H]1O[C@@H](Oc2cc(O)cc(/C=C/c3ccc(O)c(O)c3)c2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.81
▸ PTGS2 P35354 2/20 0.81
▸ GAA P10253 2/20 0.81
▸ KDM4E B2RXH2 2/20 0.81
▸ MAPT P10636 2/20 0.81
▸ G6PD P11413 1/20 0.81
▸ MAPK1 P28482 1/20 0.81
▸ ADRA1A P35348 1/20 0.81
▸ CDK5 Q00535 1/20 0.63
▸ CDK5R1 Q15078 1/20 0.63
▸ PTGS1 P23219 1/20 0.59
▸ TDP1 Q9NUW8 2/20 0.58
▸ TYR P14679 2/20 0.56
▸ AKR1B1 P15121 1/20 0.54
▸ DPP4 P27487 1/20 0.54
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Z-Astringin SCHEMBL4255439 1.00 POLB (0.81) POLBPTGS2GAAKDM4EMAPT
Z-Astringin SCHEMBL29928846 1.00 POLB (0.81) POLBPTGS2GAAKDM4EMAPT
Z-Astringin SCHEMBL4764496 1.00 POLB (0.81) POLBPTGS2GAAKDM4EMAPT
Z-Astringin SCHEMBL29428101 1.00 POLB (0.81) POLBPTGS2GAAKDM4EMAPT
Piceid SCHEMBL16419687 0.90 POLB (1.00) POLBPTGS2GAAKDM4EMAPT
Piceid SCHEMBL13252338 0.90 POLB (1.00) POLBPTGS2GAAKDM4EMAPT
Piceid SCHEMBL10182561 0.90 POLB (1.00) POLBPTGS2GAAKDM4EMAPT
SCHEMBL22522066 0.90 POLB (0.91) POLBPTGS2GAAKDM4EMAPT
Piceid SCHEMBL22111468 0.90 POLB (1.00) POLBPTGS2GAAKDM4EMAPT
Piceid SCHEMBL10148943 0.90 POLB (1.00) POLBPTGS2GAAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 706 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829555-B1 COMPOSITIONS COMPRISING RESVERATROLOSIDES AND CURCUMIN RAVAGNAN GIAMPIETRO (IT) 2026-05-13 — — EP claimed
US-12440465-B2 Nutritional compositions and associated methods NSE PRODUCTS, INC. (US) 2025-10-14 — — US claimed
WO-2025137032-A1 COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND ACTIVE AGENT L'OREAL (FR) 2025-06-26 — — WO claimed
US-20250195369-A1 COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND ACTIVE AGENT L'OREAL (FR) 2025-06-19 — — US claimed
WO-2024240989-A1 A METHOD OF IMAGING, SORTING AND TREATING WOOD ARTICLES AND ACCORDING WOOD PRODUCT METSÄLIITTO OSUUSKUNTA (FI) 2024-11-28 — — WO claimed
WO-2024199144-A1 NOVEL REAGENT FOR MITIGATING LNP TOXICITY SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) 2024-10-03 — — WO claimed
EP-4167935-A1 ASSOCIATION OF NATURAL ACTIVES INGREDIENTS TO FIGHT SKIN AGING Tomcat International Limited (GB) 2023-04-26 — — EP claimed
US-11554132-B2 Compositions comprising resveratrolosides and curcumins Ravagnan, Giampietro (IT) 2023-01-17 — — US claimed
US-11318136-B2 Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease YOO SEUNG HYUN (US) 2022-05-03 — — US claimed
WO-2021254637-A1 ASSOCIATION OF NATURAL ACTIVES INGREDIENTS TO FIGHT SKIN AGING TOMCAT INTERNATIONAL LIMITED (GB) 2021-12-23 — — WO claimed
US-20080103103-A1 Reagents and methods to treat ocular diseases and infection INSITE VISION INCORPORATED 2008-05-01 — — US claimed
EP-1845957-A1 METHOD FOR PRODUCING A DRUG EXTRACT THAT CONTAINS HYDROXYSTILBENE Heger, Peter (DE) 2007-10-24 — — EP claimed
CN-101026959-A Fungicidally active polymer dispersions and use thereof CELANESE EMULSIONS GMBH (DE) 2007-08-29 — — CN claimed
EP-1796459-A2 FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF Celanese Emulsions GmbH (DE) 2007-06-20 — — EP claimed
WO-2007020673-A1 USE OF GLUCOSYLATED HYDROXYSTILBENES FOR THE PREVENTION AND TREATMENT OF EYE PATHOLOGIES TUBILUX PHARMA S.P.A. (IT) 2007-02-22 — — WO claimed
WO-2006082071-A1 METHOD FOR PRODUCING A DRUG EXTRACT THAT CONTAINS HYDROXYSTILBENE HEGER PETER (DE) 2006-08-10 — — WO claimed
WO-2006034762-A2 FUNGICIDALLY ACTIVE POLYMER DISPERSIONS AND USE THEREOF CELANESE EMULSIONS GMBH (DE) 2006-04-06 — — WO claimed
WO-2005012507-A1 PRODUCTION OF PLANT SECONDARY METABOLITES USING ADSORPTION AND ELICITATION IN CELL SUSPENSION CULTURE THE UNIVERSITY OF MELBOURNE (AU) 2005-02-10 — — WO claimed
WO-2005000780-A1 PIPERAZINE SALTS OF HYDROXYCINNAMIC ACIDS AND HYDROXYSTILBENES UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2005-01-06 — — WO claimed
WO-2000021507-A2 PHARMACEUTICALLY ACTIVE COMPOSITION BOCKELMANN ANDREAS (CH) 2000-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11554132-B2 Compositions comprising resveratrolosides and curcumins RB1, GLRX3, KEAP1 POLB 4489/4885PTGS2 36/4885GAA 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.